

A031 Effect of a new iridoid, patridoid I, isolated from *Patrinia saniculaefolia*, on the arachidonic acid cascade related enzymesH. Jung^a, R.B. An^b, K.H. Bae^b, K.H. Son^c, H. P. Kim^d, S. S. Kang^e and H. W. Chang^a^a College of Pharmacy, Yeungnam University, Kyongsan, 712-749, Korea. ^b College of Pharmacy, Chungnam National University. ^c Department of Food and Nutrition, Andong National University, Andong, 760-749, Korea. ^d College of Pharmacy, Kangwon, Korea ^e Natural Products Research Institute, Seoul National University, Seoul, 110-460, Korea.

Patrinia scabiosaefolia Hemsly (Valerianaceae) is an endemic in Korea and the root of genus *Patrinia* has been used in Korean traditional medicine for the treatment of various diseases including inflammation and edema, appendicitis and abscesses. For an attempt to develop of anti-inflammatory compounds from from *P. saniculaefolia*, we isolated a new type of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) dual inhibitor, patridoid I. From the MeOH extract of *P. saniculaefolia*, bioassay guided fractionation by chromatographic separation of the extract led to the isolation of patridoid I. Bone marrow derived mast cells (BMDC) were obtained from the Balb/cj mice which were cultured for up to 4 weeks in the presence of 50% WEHI-3 cells conditioned medium. To examine the effects of patridoid I on the arachidonic acid cascade related enzymes, we used several *in vitro* assay systems. As results, patridoid I did not inhibit secretory type IIA and cytosolic phospholipase A₂ activity. Interestingly, this compound inhibited both COX-2 dependent delayed PGD₂ production (IC₅₀=40 μM) and 5-LO dependent LTC₄ production by BMDC in the presence of c-Kit ligand, IL-10 and LPS (IC₅₀=40 μM). But, this compound did not affect platelet activating factor (PAF) acetyltransferase activity. When patridoid I (1R,**3R**,5R,7R) changed to its isomer patridoid II (1R,**3S**,5R,7R), patridoid II inhibited neither COX-2 nor 5-LO activity. Our results suggest that patridoid I could become a leading compound for developing a novel type of anti-inflammatory, anti-asthmatic drugs that target COX-2 as well as 5-LO.

Acknowledgement: This research was supported by a grant (PF002104-01) from Plant Diversity Research Center of 21st Century Frontier Research Program funded by Ministry of Science and Technology of Korean government.

A032 Antiulcerogenic effect of *Rumex patientia* L.L.Ö. Demirezer^a, H. Süleyman^b and A. Kuruüzüm-Uz^a^a Hacettepe University Faculty of Pharmacy Dept. of Pharmacognosy, 06100 Ankara, Turkey. ^b Atatürk University Faculty of Medicine Dept. of Pharmacology, Erzurum, Turkey.

The genus *Rumex* (Polygonaceae) is represented by 25 species in the flora of Turkey (1). *Rumex patientia* L. has been investigated both from a phytochemical (2-4) and biological viewpoint; extracts have been screened for anti-inflammatory (5-6) analgesic, antipyretic (7) and gastroprotective (8) activities.

Formation of free radicals play roles on ethanol induced GIS damages (9). COX-2 selective inhibitors possessed antioxidant effect (10). In our previous study, we confirmed antioxidant effect of *Rumex patientia* (11)

The aim of this study was to investigate the effect of D-1 (aqueous extract of *Rumex patientia*), on indomethacin and ethanol induced ulcer models in rats in comparison with synthetic compounds, nimesulide, rofecoxib and celecoxib which were selective inhibitors of COX-2 (cyclooxygenase).

Adult male wistar albino rats, weighing between 185-200 g were used.

In indomethacin induced ulcers, the ulcer area of D-1 administered rats is 3 mm² smaller than control group. The effect of D-1 and COX-2 selective inhibitors were ranged as follows: nimesulide (100 mg/kg) > rofecoxib (25 mg/kg) > D-1 (150 mg/kg) > celecoxib (100 mg/kg).

D-1 and COX-2 selective inhibitors are effective as well as famotidine on ethanol induced ulcers. The ulcer area of D-1 is 84.7 mm² smaller than control group. The efficacy of the drugs are nimesulide (100 mg/kg) > rofecoxib (25 mg/kg) > famotidine (40 mg/kg) > D-1 (150 mg/kg) > celecoxib (100 mg/kg), respectively.

References: 1. Davis P.H., (1967) Flora of Turkey and East Aegean Islands Vol. 2. 2. Demirezer, L.Ö., et al., (2001), Phytochemistry 56 (4): 399. 3. Demirezer, L. Ö., et al., (2001), Phytochem., 58: 1213. 4. Kuruüzüm, A., et al., (2001), J. Nat. Prod. 64 (5): 688. 5. Süleyman, H., et al., (1999) J. Ethnopharmacol. 65: 141. 6. Süleyman, H., et al., (2001) Pharmazie, 56: 92. 7. Süleyman, H., et al., (2001), 56 (10) 15 8. Süleyman, H., et al., (2002), Pharmazie 57 (3): 204. 9. Smith et al. (1996) Dig. Dis. Sci., 41: 1157. 10. Kotsinos et al., (1999), Biochem. and Biophys. Res. 254: 651. 11. Çetinkaya, Ö., et al., (in press).